Literature DB >> 994022

Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain.

B K Koe.   

Abstract

Several compounds of relatively rigid molecular structure have been found to exert strong blockade of monoamine uptake by synaptosomal preparations of rat corpus striatum (dopamine and serotonin) and hypothalamus (norepinephrine). These include CP-24,441 (1R, 4S-N-methyl-4-phenyl-1,2,3,4-tetrahydro-1-naphthylamine), EXP-561 (4-phenylbicyclo[2.2.2]octan-1-amine), nomifensine and nefopam. The well-defined molecular geometry of the potent inhibitor EXP-561 is a fundamental structural/conformational requirement for uptake blocking activity for the large family of phenylbutylamine- and phenoxypropylamine-related inhibitors. The tubular configuration of EXP-561 may be the most appropriate for blocking serotonin uptake. The requisite conformation for blocking dopamine uptake appears to be defined by the combination resulting from superimposition of the CP-24,441 and nomifensine structures. The conformation defined by the combination resulting from superimposition of the CP-24-441 and desipramine structures is apparently optimal for blocking norepinephrine uptake. The conformational requirements for diphenylpropylamine-related uptake blockers may be defined by the rigid compound CP-39,332 (N-methyl-4-phenyl-1,2,3,4-tetrahydro-2-naphthylamine). The actual potency of any given inhibitor is probably modulated by additional structural and stereochemical factors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 994022

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  101 in total

1.  Pharmacological properties of EXP 561, a potential antidepressant drug.

Authors:  J Maj; G Skuza; H Sowińska; G Nowak
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

2.  Enhancement of imipramine-induced rat brain beta-adrenoreceptor desensitization by subacute co-administration of trazodone, zimelidine, quipazine or 5-hydroxytryptophan.

Authors:  A A Alhaider; A A Mustafa
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Cocaine binding sites in fetal rat brain: implications for prenatal cocaine action.

Authors:  J S Meyer; L P Shearman; L M Collins; R L Maguire
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Monoamine uptake inhibitors alter cocaine pharmacokinetics.

Authors:  S R Tella; S R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Effects of carbamazepine and anti-depressant drugs on endogenous catecholamine levels in the cerebroventricular compartment of the rat.

Authors:  S Kowalik; M Levitt; A I Barkai
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Inhibitory synaptic potentials recorded from mammalian neurones prolonged by blockade of noradrenaline uptake.

Authors:  A Surprenant; J T Williams
Journal:  J Physiol       Date:  1987-01       Impact factor: 5.182

7.  Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors:  T S Rao; G B Baker; R T Coutts
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

8.  Interactions of amineptine with the neuronal dopamine uptake system: neurochemical in vitro and in vivo studies.

Authors:  J J Bonnet; A Chagraoui; P Protais; J Costentin
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Effect of adrenalectomy on the initiation and expression of cocaine-induced sensitization.

Authors:  B M Prasad; C Ulibarri; P W Kalivas; B A Sorg
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

10.  Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs.

Authors:  S O Ogren; K Fuxe; L F Agnati; J A Gustafsson; G Jonsson; A C Holm
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.